用mogamulizumab治疗的患者的心血管不良事件
Jennifer M Kwan1, Mariana L Henry1, Kirstin Cook2
1Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
概括
在4.3%的患者中,莫加穆利祖马布治疗可能导致不良心血管事件 (ACE),包括心力衰竭和心律失常. 这些事件与高死亡率有关,在老年患者和亚洲国家更频繁地发生.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药物监督 药物监督 药物监督
背景情况:
- 莫加穆利祖马布是T细胞白血病和淋巴瘤的关键治疗方法.
- 在mogamulizumab治疗后的不良心血管事件 (ACE) 之前没有研究过.
研究的目的:
- 为了研究mogamulizumab治疗后ACE的发生.
- 在接受mogamulizumab.com的患者中描述ACE的类型和结果.
主要方法:
- 世界卫生组织VigiBase数据库的分析 (2013年1月 - 2019年8月).
- 确定所有不良事件,特别是ACE,mogamulizumab治疗后.
- 在ACE的定义中,包括心脏死亡,心肌梗塞,心力衰竭,心肌炎,心律失常,血管炎,血栓形成,心和新高血压.
主要成果:
- 在接受莫加穆利祖马布治疗的患者中,ACE发生在4.3% (28/650) 的患者中.
- 心力衰竭 (42.8%) 和心室节律失常 (17.85%) 是最常见的ACE.
- ACE占致命不良结果的10%,其中25%的ACE是致命的.
- 与非心血管事件 (平均73天) 相比,ACE (平均7.7天) 的致命结局发生的时间明显较早.
- 在65岁以上的患者和亚洲国家观察到ACE发病率增加.
结论:
- 心血管毒性是mogamulizumab治疗的潜在早期不良结果.
- 与mogamulizumab治疗相关的ACE具有很高的死亡风险.
- 监测心血管并发症对于接受莫加穆利祖马布治疗的患者至关重要,特别是在特定的人口和地理群体.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
3.5K
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500
01:19Pharmacovigilance
830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K